









市場行情
/
股票
/
nasdaq-regn
/

Regeneron Pharmaceuticals Inc

REGN

749.790USD

+3.430+0.46%

收盤 12/17, 16:00（美東）報價延遲15分鐘

78.95B總市值

17.29本益比TTM



Regeneron Pharmaceuticals Inc

749.790

+3.430+0.46%

概覽公司財務分析

概覽

公司

財務

分析

關於 Regeneron Pharmaceuticals Inc 公司

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Regeneron Pharmaceuticals Inc簡介



公司代碼REGN

公司名稱Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

CEOSchleifer (Leonard S)

員工數量15106

證券類型Ordinary Share

年結日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編10591

電話17813705000

網址https://www.regeneron.com/

公司代碼REGN

上市日期Apr 02, 1991

CEOSchleifer (Leonard S)

Regeneron Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

56.41K

+3.71%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+2.47%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

37.73K

+5.04%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+10.31%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

15.51K

+7.93%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

56.41K

+3.71%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+2.47%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

37.73K

+5.04%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

其他

421.70M

11.47%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

其他

421.70M

11.47%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

8.71%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

其他

74.20%

持股股東

佔比

The Vanguard Group, Inc.

8.71%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

其他

74.20%

股東類型

持股股東

佔比

Investment Advisor

45.11%

Investment Advisor/Hedge Fund

30.91%

Hedge Fund

5.04%

Pension Fund

2.69%

Research Firm

2.61%

Bank and Trust

2.25%

Individual Investor

2.06%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

其他

7.90%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.37M

+14.55K

+0.16%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.67M

5.44%

-75.61K

-1.32%

Jun 30, 2025

State Street Investment Management (US)

4.83M

4.64%

+42.34K

+0.88%

Jun 30, 2025

Dodge & Cox

3.83M

3.67%

+1.50M

+64.64%

Jun 30, 2025

JP Morgan Asset Management

2.82M

2.7%

-1.26M

-30.95%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.47M

2.37%

-4.53K

-0.18%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

2.17M

2.09%

-7.70K

-0.35%

Aug 31, 2025

Putnam Investment Management, L.L.C.

2.03M

1.95%

+116.30K

+6.08%

Jun 30, 2025

Capital World Investors

1.97M

1.89%

+27.38K

+1.41%

Jun 30, 2025

Loomis, Sayles & Company, L.P.

1.94M

1.86%

+305.09K

+18.65%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

ProShares Ultra Nasdaq Biotechnology

佔比6.6%

Invesco Nasdaq Biotechnology ETF

佔比6.55%

Amplify Weight Loss Drug & Treatment ETF

佔比6.4%

iShares Biotechnology ETF

佔比5.9%

Simplify Health Care ETF

佔比5.54%

VanEck Biotech ETF

佔比5.51%

Invesco Biotechnology & Genome ETF

佔比5.4%

iShares Genomics Immunology and Healthcare ETF

佔比4.97%

First Trust NASDAQ Pharmaceuticals ETF

佔比4.36%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.88%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Regeneron Pharmaceuticals Inc的前五大股東是誰？



Regeneron Pharmaceuticals Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：9.37M
佔總股份比例：9.00%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.67M
佔總股份比例：5.44%。
State Street Investment Management (US)
持有股份：4.83M
佔總股份比例：4.64%。
Dodge & Cox
持有股份：3.83M
佔總股份比例：3.67%。
JP Morgan Asset Management
持有股份：2.82M
佔總股份比例：2.70%。

Regeneron Pharmaceuticals Inc的前三大股東類型是什麼？



Regeneron Pharmaceuticals Inc 的前三大股東類型分別是：
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)